In a report issued on August 8, Sean Lavin from BTIG maintained a Hold rating on Accelerate Diagnostics (AXDX). The company’s shares closed on Friday at $17.31.
According to TipRanks.com, Lavin is a 4-star analyst with an average return of 2.9% and a 53.6% success rate. Lavin covers the Healthcare sector, focusing on stocks such as Establishment Labs Holdings Inc, Helius Medical Technologies, and Tactile Systems Technology.
Accelerate Diagnostics has an analyst consensus of Moderate Buy, with a price target consensus of $19.
See today’s analyst top recommended stocks >>
Based on Accelerate Diagnostics’ latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $20.82 million. In comparison, last year the company had a GAAP net loss of $23.23 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Accelerate Diagnostics, Inc. is an in vitro diagnostics company, which engages in the provision of solutions that improve patient outcomes and lower healthcare costs through the rapid diagnosis of serious infections.
